OKYO Pharma Limited(OKYO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 5:20 PM ET (Korea 10/31 06:20)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.19 | Insider Own | 32.09% | Shs Outstand | 52.5M | Perf Week | 5% |
| Market Cap | 0.08B | Forward P/E | - | EPS next Y | -200% | Insider Trans | - | Shs Float | 35.6M | Perf Month | 9.7% |
| Enterprise Value | 0.06B | PEG | - | EPS next Q | -0.04 | Inst Own | 20.1% | Short Float | 0.22% | Perf Quarter | -11.98% |
| Income | -0.01B | P/S | - | EPS this Y | 20.59% | Inst Trans | 0.68% | Short Ratio | 1.18 | Perf Half Y | -11.45% |
| Sales | 0.00B | P/B | 6.25 | EPS next 5Y | - | ROA | -72.6% | Short Interest | 0.08M | Perf YTD | -28.99% |
| Book/sh | 0.24 | P/C | 3.75 | EPS past 3/5Y | 26.21% -116.82% | ROE | -263.78% | 52W High | -54.06% ($3.20) | Perf Year | -43.46% |
| Cash/sh | 0.39 | P/FCF | - | Sales past 3/5Y | - | ROIC | -72.55% | 52W Low | 16.22% ($1.26) | Perf 3Y | -8.13% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -39.9% | Gross Margin | - | Volatility(W/M) | 6.03% 6.36% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.09 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.43 | EPS Q/Q | -115.28% | Profit Margin | - | RSI (14) | 52.83 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.43 | Sales Q/Q | - | SMA20 | 1.9% ($1.44) | Beta | 0.05 | Target Price | $6 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/06/03 | SMA50 | 1.88% ($1.44) | Rel Volume | 1.66 | Prev Close | $1.5 |
| Employees | - | LT Debt/Eq | 0 | EPS/Sales Surpr. | -87.5% - | SMA200 | -8.99% ($1.62) | Avg Volume(3M) | 0.06M | Price | $1.47 |
| IPO | 2022/5/17 | Option/Short | No/Yes | Trades | 145 | Volume | 107,544 | Change | -2% |
A clinical-stage biotechnology company developing innovative treatments for inflammatory eye diseases, targeting dry eye disease and neuropathic corneal pain (NCP). Leveraging its proprietary ChemR23 receptor agonist technology, the company is advancing next-generation ophthalmic drugs that simultaneously address eye pain and inflammation—issues that existing therapies have failed to resolve.
Over the past 1 year, on the lower side
54% below its 1-year high.
Traded more than usual. That is 166% of its average volume.
OKYO has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by +20.6% this year.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 3 years ago, your return today would be -8.1%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 20.1%.
Tap to view numbers
It ranks #381 of 597 in the industry
Based on market cap of $77M.
ATRA#378 Atara Biotherapeutics Inc $80M PER - 
CNXU#379 Conexeu Sciences Inc $78M PER - 
CLLS#380 Cellectis ADR $78M PER - OKYO#381 OKYO Pharma Limited $77M PER - 
NTRB#382 Nutriband Inc $77M PER - 
FAQ
What kind of company is OKYO?
OKYO belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of OKYO?
The market cap of OKYO is approximately $77M, ranking 4,618 within its sector.
What is the 52-week high and low for OKYO?
OKYO has recorded a 52-week high of $3.20 and a low of $1.26.
